Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2026)

Contineum Therapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at -$253000.0 for Q1 2026.

• On a quarterly basis, Retained Earnings rose 99.81% year-over-year to -$253000.0 in Q1 2026; TTM through Mar 2026 was -$253000.0, a 99.81% increase from a year earlier, with the FY2025 full-year figure at $260000.0, down 99.92% from the prior year.
• Retained Earnings retreated to -$253000.0 in Q1 2026 per CTNM's latest filing, from $260000.0 in the prior quarter.
• Across five years, Retained Earnings topped out at $315.4 million in Q4 2024 and bottomed at -$162.2 million in Q3 2025.
• The 4-year median for Retained Earnings is -$88.1 million (2024), against an average of -$40.2 million.
• Across the five-year window, Retained Earnings soared 4343.1% in 2024 and sank 99.92% in 2025, its largest moves.
• Year by year, Retained Earnings stood at $7.1 million in 2023, then surged by 4343.1% to $315.4 million in 2024, then sank by 99.92% to $260000.0 in 2025, then slumped by 197.31% to -$253000.0 in 2026.
• Per Business Quant, the three latest CTNM Retained Earnings figures stand at -$253000.0 (Q1 2026), $260000.0 (Q4 2025), and -$162.2 million (Q3 2025).